|
FY2026
12 months to Jun 27, 2026
|
FY2025
12 months to Jun 28, 2025
|
FY2024
12 months to Jun 29, 2024
|
FY2023
12 months to Jul 1, 2023
|
FY2022
12 months to Jul 2, 2022
|
|
|---|---|---|---|---|---|
| Net revenue | |||||
| Cost of sales | |||||
| Amortization of acquired developed intangibles | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Restructuring and related charges | |||||
| Impairment charges | |||||
| Gain on sale of facility | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Loss on debt extinguishment | |||||
| Escrow settlement | |||||
| Interest expense | |||||
| Other income, net | |||||
| Total other (expense) income, net | |||||
| Loss before income taxes | |||||
| Income tax (benefit) provision | |||||
| Net (loss) income | |||||
| Net (loss) income per share: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Shares used to compute net (loss) income per share - common stock and preferred stock assuming conversion: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...